Zydus receives final approval from the USFDA for Methotrexate Tablets USP

Zydus receives final approval from the USFDA for Methotrexate Tablets USP _______________________________________________________ Ahmedabad, 18 January 2017 Zydus Cadila has received the final approval from the USFDA to market Methotrexate Tablets USP, 2.5 mg, a chemotherapy drug used for leukemias, lymphomas, breast cancer, lung cancer, head and neck cancers and other cancers. The drug will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. Th e group now has more than 105 approvals and has so far filed nearly 275 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 19,500 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗